RxDoctor Payments Data

Ramon Raneses, MD

Cardiovascular Disease · Grand Blanc, MINPI 1205812856

Payments from drug & device makers

$2,844in general payments, 2019–2025

Across 135 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$812
  • Novartis$496
  • Shockwave Medical, Inc$276
  • Abiomed$146
  • Amgen$145
  • Kiniksa Pharmaceuticals, Ltd.$111
  • plus $857 from 23 others

What the payments were for

  • Grants$552%
  • Food & beverage$2,78998%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,844 in reported general payments places this provider in the 45th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$204,142
Medicare patients
490
Services billed
2,682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$159,146
XareltoRivaroxaban103$127,311
EntrestoSacubitril/Valsartan53$68,269
Repatha SureclickEvolocumab22$29,316
JardianceEmpagliflozin14$19,345
Isosorbide Mononitrate ErIsosorbide Mononitrate141$2,822
Atorvastatin Calcium152$2,642
Diltiazem 24hr Er (Cd)Diltiazem Hcl59$1,805
Metoprolol Succinate88$1,672
ClopidogrelClopidogrel Bisulfate74$1,546
Metoprolol Tartrate171$1,306
Flecainide Acetate20$1,301
Amiodarone Hcl22$981
Amlodipine Besylate98$858
Lisinopril103$824

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$41$159,146127 claims
Johnson & JohnsonXarelto$20$127,311103 claims
NovartisEntresto$496$68,26953 claims
Boehringer IngelheimJardiance$48$19,34514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Grand Blanc

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →